Navigation Links
New study suggests cause of debilitating skin condition
Date:9/24/2007

WINSTON-SALEM, N.C. New findings from researchers at Wake Forest University Baptist Medical Center and colleagues suggest why some people with kidney failure can develop a rare tightening and swelling of the skin and other organs, including the lungs and heart.

Reporting in the October issue of the American Journal of Dermatopathology, the authors suggest a possible explanation for why some patients on kidney dialysis who are injected with a contrast agent during a magnetic resonance imaging (MRI) develop nephrogenic systemic fibrosis (NSF).

The U.S. Food and Drug Administration now requires a warning about the potential risk on the products labels. NSF leads to thickened, rough or hard skin usually on the arms, legs or trunk. In some cases, the limbs can become difficult or even impossible to move.

The cause of this syndrome has been unclear, said David C. Sane, M.D., senior researcher on the project. Our research suggests both a potential cause and the possibility of preventing or treating NSF.

Sane said the finding that an enzyme known as transglutaminase-2 (TG2) may be involved is the first to suggest how exposure to contrast agents may lead to NSF.

It has not been known what causes NSF, but a risk factor is exposure to gadolinium, an agent injected into patients veins during some MRI procedures to help improve the visibility of internal organs during the test. The condition is relatively rare it occurs in about 2 percent to 4 percent of kidney patients on dialysis who are exposed to gadolinium.

The researchers tested the hypothesis that TG2 may be involved in the response. The enzyme is found throughout the body and is involved in blood clotting and wound healing. They hypothesized that gadolinium may activate the enzyme and cause NSF.

The group obtained skin biopsies from five people with NSF and three healthy people. All NSF patients had renal failure and had previously had imaging procedures using gadolinium. The researchers tested for the presence of TG2 in the skin samples.

Compared to the healthy subjects, there was a marked increase in TG2 in the subjects with NSF, said Sane. This suggests that activation of TG2 can produce the syndrome. TG2 is expressed in virtually all tissues and may explain why the fibrosis can occur in the heart and lungs, as well as the skin.

Sane said the results also suggest a strategy for preventing or treating NSF drugs such as cysteamine that inhibit the activation of TG-2.

Our research is a pilot study, but we believe the results warrant further research into the use of TG-2 inhibitors in the treatment and prevention of NSF, said Gil Yosipovitch, M.D., co-senior researcher, and a dermatologist. Solving this puzzle might allow dialysis patients to take full advantage of the diagnostic capabilities of MRI.

This could be a general mechanism for a broad range of disorders that involve fibrosis, or tissue thickening, said Sane.


'/>"/>

Contact: Karen Richardson
krchrdsn@wfubmc.edu
336-716-4453
Wake Forest University Baptist Medical Center
Source:Eurekalert

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and ... in Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate ... with today’s savvy consumer, and the latest in hearing technology. At the event, ...
(Date:6/27/2017)... ... June 27, 2017 , ... Atmosera , ... Atmosera Managed Azure Services . The trusted, transparent, and secure solution for the ... growing customer base. Atmosera’s next generation services include integrated capabilities for public, private, ...
(Date:6/27/2017)... ... June 27, 2017 , ... A+ Orthodontics is ... specialty that focuses on treating alignment and occlusion irregularities. Treatment often includes the ... , North Hollywood dentist , Dr. Garemani, along with Dr. Reza and ...
(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, ... with the Fertility Center of California, is pleased to announce the addition of ... and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... ... coding staff, and consumers are seeing lots of red these days. According to ... inaccurate charges that result from medical coding errors(1). Some studies point to Electronic ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/2/2017)... 2, 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical ... new findings demonstrating positive biochemical outcomes related to more ... The data will be presented at the ERA-EDTA Congress ... Spain . The research was ... Network in Europe (KIHDNEy) ...
(Date:5/29/2017)... AVIV, Israel, May 29, 2017  Cellect Biotechnology Ltd. ... innovative technology which enables the functional selection of stem ... results for the first quarter ended March 31 st ... with our accomplishments in the first quarter of 2017," ... first quarter, we announced the treatment of the first ...
Breaking Medicine Technology: